Genmab A/S (GMAB) Competitors

argenex (NASDAQ:ARGX) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

Is ARGX or GMAB more profitable?

argenex has a net margin of 40.98% compared to Genmab A/S's net margin of 37.53%. argenex's return on equity of 21.06% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	40.98%	21.06%	18.25%
Genmab A/S	37.53%	21.03%	16.98%

Which has more risk and volatility, ARGX or GMAB?

argenex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in ARGX or GMAB?

60.3% of argenex shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Which has preferable earnings and valuation, ARGX or GMAB?

Genmab A/S has higher revenue and earnings than argenex. Genmab A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$2.25B	22.35	$833.04M	$19.50	41.91
Genmab A/S	$3.12B	6.15	$1.14B	$1.99	15.02

Does the media favor ARGX or GMAB?

In the previous week, argenex had 2 more articles in the media than Genmab A/S. MarketBeat recorded 15 mentions for argenex and 13 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.80 beat argenex's score of 0.44 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Do analysts prefer ARGX or GMAB?

argenex presently has a consensus target price of $817.53, indicating a potential upside of 0.03%. Genmab A/S has a consensus target price of $40.80, indicating a potential upside of 36.50%. Given Genmab A/S's higher possible upside, analysts clearly believe Genmab A/S is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	3 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.92
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Summary

argenex beats Genmab A/S on 11 of the 17 factors compared between the two stocks.